Moderna (MRNA) Returns to Profit in Q3 with Strong Revenue Growth and Raised 2026 Outlook

Key Takeaways

• Moderna reported third quarter 2026 revenue of $1.31 billion, up 29% year over year, driven by stronger international COVID-19 vaccine sales.
• The company swung to a net income of $162 million and diluted earnings per share (EPS) of $0.38, compared with a net loss of $200 million, or $0.51 per share, a year earlier.
• Results came in well ahead of consensus, with revenue and EPS both exceeding analyst estimates by a wide margin.
• Management raised its full-year 2026 revenue growth outlook to 15%–25%, up from a prior framework of "up to 10%."
• Research and development (R&D) expenses fell 27% year over year to $583 million as late-stage infectious disease studies wound down.
• Cash and investments climbed to $8 billion at quarter-end, supported by convertible note proceeds.

Why This Quarter Matters

Moderna's third quarter report carries outsized weight because it lands in the company's peak respiratory-vaccine season, when the majority of its annual COVID-19 vaccine sales are recorded. After years of shrinking demand and mounting losses, investors are watching closely for evidence that the company's pivot toward international government partnerships, new product approvals, and aggressive cost discipline can deliver a sustainable return to profitability. The quarter also tested management's credibility on its multiyear turnaround plan, including its stated goal of reaching cash breakeven. With the stock having surged dramatically in 2026, the results and updated guidance offered a key checkpoint on whether that rally is supported by fundamentals.

Breaking Down the Reported Results

Moderna reported total revenue of $1.313 billion for the third quarter of 2026, a 29.2% increase from $1.02 billion in the prior-year period and well above consensus estimates of roughly $885 million to $902 million. Net product sales rose 30.8% to $1.27 billion, led by higher international COVID-19 vaccine deliveries under long-term government partnerships. U.S. revenue totaled $780 million, while international revenue reached $533 million.

The company posted net income of $162 million, a $362 million improvement from the $200 million loss a year earlier. Diluted EPS came in at $0.38, compared with a loss of $0.51 per share last year, and far exceeded consensus expectations of a loss of roughly $1.10 to $1.26 per share. Operating income was $130 million versus an operating loss of $260 million in the prior-year quarter.

On the cost side, cost of sales rose 54% to $318 million, representing 24% of revenue, reflecting higher product volume. R&D expenses declined 27% to $583 million, while selling, general, and administrative (SG&A) expenses rose 5% to $282 million. The company ended the quarter with $8 billion in cash and investments, up from $6.9 billion at the end of the second quarter, boosted by $2.6 billion in net proceeds from a convertible note issuance, partially offset by a $950 million litigation settlement payment.

Management also raised full-year 2026 revenue guidance to 15%–25% growth, from a prior outlook of up to 10%, and reduced its full-year R&D spending forecast to about $2.7 billion from $2.9 billion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

MRNA shares moved higher in trading following the release, with reports indicating a gain of roughly 5% to 8% in the morning session, as investors digested the surprise return to profitability and the raised full-year outlook. The magnitude of the EPS beat, which landed well above consensus expectations, appeared to be the primary catalyst, alongside the more optimistic revenue guidance. Sentiment had been improving into the report, with the stock up sharply on a year-to-date basis, and the results reinforced the view that international partnerships and disciplined spending are reshaping the company's financial trajectory. Still, investors noted that the profit arrived during Moderna's strongest seasonal quarter and was aided materially by lower R&D spending, tempering some of the enthusiasm.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Moderna can sustain its momentum beyond the seasonal COVID-19 vaccination peak. Management's raised full-year revenue growth outlook of 15%–25% signals confidence in the fourth quarter and in the durability of its international government partnerships across Canada, the U.K., and Australia. The company expects its full-year revenue mix to be roughly even between the U.S. and international markets, a meaningful shift from its historically U.S.-heavy base.

Cost discipline remains a central theme. With R&D guidance lowered to about $2.7 billion and capital expenditures reduced to roughly $200 million, investors will watch whether the company can keep trimming expenses without sacrificing its pipeline. The wind-down of late-stage infectious disease trials has been a key driver of savings, but future growth depends on new product approvals and pipeline readouts.

Beyond the near term, attention will turn to the company's oncology programs, including positive Phase 3 results for intismeran in melanoma announced during the quarter, as well as additional data readouts and regulatory approvals. Progress toward the stated goal of cash breakeven by 2028 remains a longer-term benchmark that will shape investor confidence in the stock's valuation. Litigation-related costs and any shifts in global vaccination rates are additional factors worth monitoring. From what I see, the raised guidance and cost controls stand out as particularly encouraging signs.

Using AI Tools in My Research Process

I often turn to Tickeron’s AI Screener when evaluating earnings reports like this one. It lets me quickly filter stocks by fundamentals, technical patterns, and AI signals to compare MRNA against peers and spot potential opportunities or risks. In this case, it helped confirm how the improved profitability metrics stack up against other biotech names, giving me a broader perspective before forming a view on the quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume